


First Clinical Research Stock Index (FCRI)

Market Activity

FCRI gained 3% last month, while biotechs were flat, pharmas declined 2%, and the general market gained 1%. Six FCRI stocks gained and three declined. Significant gainers included CMIC (+19%), INC Research Holdings (+14%), Hangzhou Tigermed Consulting Co Ltd (+14%), and PRA Health Sciences (+11%). There were no significant decliners.



Notes on Indices

- **First Clinical Research Index (FCRI).** Calculated as the mean average percentage change from baseline, dividends excluded, adjusted for stock splits. In other words, the indices are not weighted for stock price or market capitalization. Prices are in local currencies. Index components may change from time to time based on new listings, mergers and other factors. Components include 10 publicly traded clinical research stocks: CMIC (2309:JP), EPS Co., Ltd. (4282:JP), Hangzhou Tigermed Consulting Co Ltd (300347:CH), ICON (ICLR:US), INC Research Holdings (INCR:US), IQvia Holdings (IQV:US), Medidata (MDSO:US), Medpace Holdings (MEDP:US), and PRA Health Sciences (PRAH:US).
- **S&P 500 Index (SPX).** Capitalization-weighted representative sample of 500 mostly large-capitalization companies in leading industries of the U.S. economy.
- **S&P 500 Pharmaceutical Index (S5PHARX).** Capitalization-weighted S&P 500 companies engaged in research, development or production of pharmaceuticals.
- **S&P 500 Biotechnology Index (S5BIOTX).** Capitalization-weighted S&P 500 companies primarily involved in development, manufacturing or marketing of products based on advanced biotechnology research.

Stock and index prices are available at <http://www.bloomberg.com/> and <http://bigcharts.marketwatch.com/industry/bigcharts-com/industrychart.asp>